Anika Therapeutics Stock Price, News & Analysis (NASDAQ:ANIK)

$53.13 0.63 (1.20 %)
(As of 12/14/2017 04:00 PM ET)
Previous Close$52.50
Today's Range$52.12 - $53.86
52-Week Range$41.64 - $60.29
Volume52,300 shs
Average Volume97,844 shs
Market Capitalization$769.74 million
P/E Ratio24.65
Dividend YieldN/A
Beta1.46

About Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics logoAnika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company's therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company's ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.

Receive ANIK News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ANIK
CUSIP03525510
Phone781-457-9000

Debt

Debt-to-Equity RatioN/A
Current Ratio17.01%
Quick Ratio15.28%

Price-To-Earnings

Trailing P/E Ratio24.65
Forward P/E Ratio27.96
P/E Growth2.76

Sales & Book Value

Annual Sales$103.38 million
Price / Sales7.53
Cash Flow$2.51 per share
Price / Cash21.16
Book Value$15.23 per share
Price / Book3.49

Profitability

Trailing EPS$2.13
Net Income$32.54 million
Net Margins28.23%
Return on Equity13.40%
Return on Assets12.41%

Miscellaneous

Employees122
Outstanding Shares14,660,000

Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics Inc. (NASDAQ:ANIK) posted its quarterly earnings results on Wednesday, October, 25th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.05. The biotechnology company had revenue of $27.18 million for the quarter, compared to analyst estimates of $27.44 million. Anika Therapeutics had a return on equity of 13.40% and a net margin of 28.23%. Anika Therapeutics's revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period last year, the company earned $0.59 EPS. View Anika Therapeutics' Earnings History.

When will Anika Therapeutics make its next earnings announcement?

Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for Anika Therapeutics.

Where is Anika Therapeutics' stock going? Where will Anika Therapeutics' stock price be in 2017?

1 equities research analysts have issued 12-month target prices for Anika Therapeutics' stock. Their forecasts range from $57.00 to $57.00. On average, they expect Anika Therapeutics' share price to reach $57.00 in the next twelve months. View Analyst Ratings for Anika Therapeutics.

Who are some of Anika Therapeutics' key competitors?

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the folowing people:

  • Joseph G. Darling, President (Age 59)
  • Charles H. Sherwood Ph.D., Chief Executive Officer, Director (Age 70)
  • Sylvia Cheung, Chief Financial Officer, Treasurer, Secretary (Age 42)
  • Dana M. Alexander, Chief Operating Officer (Age 41)
  • Edward Ahn Ph.D., Chief Technology and Strategy Officer (Age 45)
  • Richard Hague, Chief Commercial Officer (Age 57)
  • Joseph Lyon Bower Ph.D., Lead Independent Director (Age 79)
  • Raymond J. Land, Independent Director (Age 72)
  • Glenn R. Larsen Ph.D., Independent Director (Age 62)
  • Jeffrey S. Thompson, Independent Director (Age 51)

Who owns Anika Therapeutics stock?

Anika Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Kayne Anderson Rudnick Investment Management LLC (11.30%), Dimensional Fund Advisors LP (6.11%), Bank of New York Mellon Corp (3.69%), Thomson Horstmann & Bryant Inc. (1.48%), Wells Fargo & Company MN (1.43%) and Stifel Financial Corp (1.22%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Jeffery S Thompson, Joseph I Bower, Raymond J Land and Richard Hague. View Institutional Ownership Trends for Anika Therapeutics.

Who sold Anika Therapeutics stock? Who is selling Anika Therapeutics stock?

Anika Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Thomson Horstmann & Bryant Inc., Ameriprise Financial Inc., Russell Investments Group Ltd., KBC Group NV, Schwab Charles Investment Management Inc., Virginia Retirement Systems ET AL, California State Teachers Retirement System and OxFORD Asset Management LLP. Company insiders that have sold Anika Therapeutics company stock in the last year include Charles H Sherwood, Jeffery S Thompson and Richard Hague. View Insider Buying and Selling for Anika Therapeutics.

Who bought Anika Therapeutics stock? Who is buying Anika Therapeutics stock?

Anika Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Kayne Anderson Rudnick Investment Management LLC, Bank of New York Mellon Corp, Sei Investments Co., Wells Fargo & Company MN, Fisher Asset Management LLC, Dimensional Fund Advisors LP, JPMorgan Chase & Co. and Stifel Financial Corp. View Insider Buying and Selling for Anika Therapeutics.

How do I buy Anika Therapeutics stock?

Shares of Anika Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anika Therapeutics' stock price today?

One share of Anika Therapeutics stock can currently be purchased for approximately $53.13.

How big of a company is Anika Therapeutics?

Anika Therapeutics has a market capitalization of $769.74 million and generates $103.38 million in revenue each year. The biotechnology company earns $32.54 million in net income (profit) each year or $2.13 on an earnings per share basis. Anika Therapeutics employs 122 workers across the globe.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]


MarketBeat Community Rating for Anika Therapeutics (ANIK)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  74 (Vote Underperform)
Total Votes:  175
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Anika Therapeutics (NASDAQ:ANIK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldBuy
Consensus Rating Score: 3.003.002.002.50
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $57.00$57.00N/A$49.50
Price Target Upside: 3.92% upside3.92% upsideN/A5.97% upside

Anika Therapeutics (NASDAQ:ANIK) Consensus Price Target History

Price Target History for Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics (NASDAQ:ANIK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/27/2017Barrington ResearchBoost Price TargetOutperform -> Outperform$53.00 -> $57.00N/AView Rating Details
4/27/2016Northland SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Anika Therapeutics (NASDAQ:ANIK) Earnings History and Estimates Chart

Earnings by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics (NASDAQ ANIK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/13/2018$0.46N/AView Earnings Details
10/25/2017Q3 2017$0.41$0.46$27.44 million$27.18 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.44$0.76$27.20 million$33.50 millionViewN/AView Earnings Details
5/3/2017Q1 2017$0.38$0.37$23.89 million$23.39 millionViewListenView Earnings Details
2/15/2017Q416$0.53$0.54$27.84 million$28.70 millionViewN/AView Earnings Details
10/26/2016Q316$0.47$0.59$26.60 million$25.79 millionViewListenView Earnings Details
7/27/2016Q216$0.44$0.57$24.75 million$26.60 millionViewListenView Earnings Details
4/27/2016Q116$0.28$0.45$19.26 million$22.30 millionViewListenView Earnings Details
2/24/2016Q415$0.60$0.72$28.19 million$25.60 millionViewListenView Earnings Details
10/28/2015Q315$0.34$0.55$22.36 million$23.70 millionViewListenView Earnings Details
7/29/2015Q215$0.34$0.51$21.65 million$22.90 millionViewListenView Earnings Details
4/28/2015Q115$0.21$0.23$16.20 million$15.50 millionViewListenView Earnings Details
2/25/2015Q414$0.48$0.51$24.60 million$23.30 millionViewListenView Earnings Details
10/29/2014Q314$0.33$0.40$20.33 million$22.10 millionViewListenView Earnings Details
7/30/2014Q214$0.57$0.60$28.20 million$26.27 millionViewListenView Earnings Details
4/29/2014Q114$0.25$0.97$16.03 million$34.00 millionViewN/AView Earnings Details
2/26/2014Q413$0.42$0.44$21.91 million$21.30 millionViewListenView Earnings Details
10/31/2013Q313$0.14$0.33$16.96 million$17.80 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.25$0.40$17.09 million$20.80 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Anika Therapeutics (NASDAQ:ANIK) Earnings Estimates

2017 EPS Consensus Estimate: $1.85
2018 EPS Consensus Estimate: $1.75
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.34$0.42$0.38
Q2 20172$0.42$0.47$0.45
Q3 20172$0.39$0.42$0.41
Q4 20172$0.62$0.62$0.62
Q1 20182$0.32$0.36$0.34
Q2 20181$0.47$0.47$0.47
Q3 20181$0.44$0.44$0.44
Q4 20181$0.50$0.50$0.50
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Anika Therapeutics (NASDAQ:ANIK)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Anika Therapeutics (NASDAQ ANIK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.57%
Institutional Ownership Percentage: 85.04%
Insider Trades by Quarter for Anika Therapeutics (NASDAQ:ANIK)
Insider Trades by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics (NASDAQ ANIK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/30/2017Richard HagueInsiderSell5,250$54.48$286,020.00View SEC Filing  
10/23/2017Charles H SherwoodCEOSell22,228$60.06$1,335,013.68View SEC Filing  
10/20/2017Charles H SherwoodCEOSell5,991$60.04$359,699.64View SEC Filing  
10/16/2017Charles H SherwoodCEOSell3,293$60.04$197,711.72View SEC Filing  
10/13/2017Charles H SherwoodCEOSell7,124$60.08$428,009.92View SEC Filing  
7/27/2017Charles H SherwoodCEOSell63,799$50.79$3,240,351.21View SEC Filing  
7/5/2017Charles H SherwoodCEOSell14,201$50.03$710,476.03View SEC Filing  
5/22/2017Jeffery S ThompsonDirectorSell10,725$47.39$508,257.75View SEC Filing  
11/9/2016Joseph I BowerDirectorSell540$43.39$23,430.60View SEC Filing  
2/25/2016Raymond J LandDirectorSell2,695$43.62$117,555.90View SEC Filing  
2/27/2015Raymond J LandDirectorSell4,621$39.49$182,483.29View SEC Filing  
5/1/2014Charles H SherwoodCEOSell83,780$44.32$3,713,129.60View SEC Filing  
2/28/2014Charles H SherwoodCEOSell200,000$41.70$8,340,000.00View SEC Filing  
8/22/2013John C MoranDirectorSell5,000$24.35$121,750.00View SEC Filing  
8/8/2013Steve E WheelerDirectorSell26,984$23.61$637,092.24View SEC Filing  
8/7/2013Steve E WheelerDirectorSell11,016$27.01$297,542.16View SEC Filing  
8/6/2013Farmaceutici S.P.A. FidiaMajor ShareholderSell1,270,000$24.52$31,140,400.00View SEC Filing  
7/15/2013Charles H SherwoodCEOSell75,000$20.11$1,508,250.00View SEC Filing  
7/9/2013Charles H SherwoodCEOSell49,185$18.06$888,281.10View SEC Filing  
7/5/2013Charles H SherwoodCEOSell34,662$18.01$624,262.62View SEC Filing  
6/19/2013Charles H SherwoodCEOSell1,847$18.00$33,246.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Anika Therapeutics (NASDAQ ANIK) News Headlines

Source:
DateHeadline
7 Quality Stocks With High Business Predictability Ratings7 Quality Stocks With High Business Predictability Ratings
finance.yahoo.com - December 14 at 3:22 PM
Reviewing Ambit Biosciences (AMBI) & Anika Therapeutics (ANIK)Reviewing Ambit Biosciences (AMBI) & Anika Therapeutics (ANIK)
www.americanbankingnews.com - December 14 at 10:06 AM
ETFs with exposure to Anika Therapeutics, Inc. : December 13, 2017ETFs with exposure to Anika Therapeutics, Inc. : December 13, 2017
finance.yahoo.com - December 13 at 3:22 PM
Zacks: Brokerages Set $57.00 Price Target for Anika Therapeutics Inc. (ANIK)Zacks: Brokerages Set $57.00 Price Target for Anika Therapeutics Inc. (ANIK)
www.americanbankingnews.com - December 11 at 5:56 AM
Brokerages Anticipate Anika Therapeutics Inc. (ANIK) to Post $0.54 EPSBrokerages Anticipate Anika Therapeutics Inc. (ANIK) to Post $0.54 EPS
www.americanbankingnews.com - December 7 at 8:34 AM
Anika Therapeutics (ANIK) and Biogen (BIIB) Financial ComparisonAnika Therapeutics (ANIK) and Biogen (BIIB) Financial Comparison
www.americanbankingnews.com - December 6 at 11:20 AM
Anika Therapeutics Inc. (ANIK) Insider Richard Hague Sells 5,250 SharesAnika Therapeutics Inc. (ANIK) Insider Richard Hague Sells 5,250 Shares
www.americanbankingnews.com - December 1 at 9:50 PM
ETFs with exposure to Anika Therapeutics, Inc. : November 27, 2017ETFs with exposure to Anika Therapeutics, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 3:18 PM
Anika Therapeutics (ANIK) and Trius Therapeutics (TSRX) Head to Head ComparisonAnika Therapeutics (ANIK) and Trius Therapeutics (TSRX) Head to Head Comparison
www.americanbankingnews.com - November 22 at 5:24 PM
Anika Therapeutics (ANIK) & Auxilium Pharmaceuticals (AUXL) Financial SurveyAnika Therapeutics (ANIK) & Auxilium Pharmaceuticals (AUXL) Financial Survey
www.americanbankingnews.com - November 22 at 3:42 PM
Analysts Expect Anika Therapeutics Inc. (ANIK) to Announce $0.54 Earnings Per ShareAnalysts Expect Anika Therapeutics Inc. (ANIK) to Announce $0.54 Earnings Per Share
www.americanbankingnews.com - November 21 at 11:42 AM
Analysts Expect Anika Therapeutics Inc. (ANIK) to Announce $0.54 Earnings Per ShareAnalysts Expect Anika Therapeutics Inc. (ANIK) to Announce $0.54 Earnings Per Share
www.americanbankingnews.com - November 21 at 11:42 AM
ETFs with exposure to Anika Therapeutics, Inc. : November 14, 2017ETFs with exposure to Anika Therapeutics, Inc. : November 14, 2017
finance.yahoo.com - November 14 at 4:22 PM
Adhesion Barrier Minimizing the Risk of Post-Operative Adhesions, to Witness CAGR of 8.6% during 2017 to 2023Adhesion Barrier Minimizing the Risk of Post-Operative Adhesions, to Witness CAGR of 8.6% during 2017 to 2023
globenewswire.com - November 10 at 2:08 PM
 Anika Therapeutics Inc. (ANIK) Receives Consensus Rating of "Strong Buy" from Analysts Anika Therapeutics Inc. (ANIK) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - November 6 at 3:42 PM
ETFs with exposure to Anika Therapeutics, Inc. : November 2, 2017ETFs with exposure to Anika Therapeutics, Inc. : November 2, 2017
finance.yahoo.com - November 2 at 4:21 PM
Anika Therapeutics, Inc. :ANIK-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017Anika Therapeutics, Inc. :ANIK-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017
finance.yahoo.com - November 1 at 4:26 PM
Anika Therapeutics, Inc. – Value Analysis (NASDAQ:ANIK) : October 30, 2017Anika Therapeutics, Inc. – Value Analysis (NASDAQ:ANIK) : October 30, 2017
finance.yahoo.com - October 30 at 4:52 PM
Anika Therapeutics Inc. (ANIK) Price Target Raised to $57.00 at Barrington ResearchAnika Therapeutics Inc. (ANIK) Price Target Raised to $57.00 at Barrington Research
www.americanbankingnews.com - October 28 at 4:52 PM
Anika Therapeutics Enters Oversold Territory (ANIK)Anika Therapeutics Enters Oversold Territory (ANIK)
www.thestreet.com - October 28 at 4:18 PM
Anika Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ANIK-US : October 27, 2017Anika Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ANIK-US : October 27, 2017
finance.yahoo.com - October 27 at 6:06 PM
Edited Transcript of ANIK earnings conference call or presentation 26-Oct-17 1:00pm GMTEdited Transcript of ANIK earnings conference call or presentation 26-Oct-17 1:00pm GMT
finance.yahoo.com - October 27 at 1:59 AM
Its A No For PTCT As Expected, SRPT Revises Outlook Higher, TSRO Gets FDA NodIt's A No For PTCT As Expected, SRPT Revises Outlook Higher, TSRO Gets FDA Nod
www.rttnews.com - October 26 at 10:31 AM
Anika Therapeutics Inc. 2017 Q3 - Results - Earnings Call SlidesAnika Therapeutics Inc. 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - October 26 at 10:31 AM
Anika Therapeutics, Inc. to Host Earnings CallAnika Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - October 26 at 10:31 AM
Anika posts 3Q profitAnika posts 3Q profit
finance.yahoo.com - October 25 at 10:05 PM
Anika Therapeutics Inc. (ANIK) Posts Quarterly  Earnings Results, Beats Estimates By $0.04 EPSAnika Therapeutics Inc. (ANIK) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - October 25 at 7:20 PM
BRIEF-Anika completes enrollment in second pivotal phase III trial of cingalBRIEF-Anika completes enrollment in second pivotal phase III trial of cingal
www.reuters.com - October 25 at 5:02 PM
Anika Completes Enrollment in Second Pivotal Phase III Trial of CINGAL for the Treatment of Knee Pain Associated with OsteoarthritisAnika Completes Enrollment in Second Pivotal Phase III Trial of CINGAL for the Treatment of Knee Pain Associated with Osteoarthritis
finance.yahoo.com - October 25 at 5:02 PM
Anika Reports Third Quarter 2017 Financial ResultsAnika Reports Third Quarter 2017 Financial Results
finance.yahoo.com - October 25 at 5:02 PM
Anika Therapeutics Inc. (ANIK) CEO Sells $359,699.64 in StockAnika Therapeutics Inc. (ANIK) CEO Sells $359,699.64 in Stock
www.americanbankingnews.com - October 24 at 4:14 PM
Anika Therapeutics Inc. (ANIK) CEO Sells $1,335,013.68 in StockAnika Therapeutics Inc. (ANIK) CEO Sells $1,335,013.68 in Stock
www.americanbankingnews.com - October 24 at 4:14 PM
Anika Announces the Forthcoming Appointment of Thomas M. Finnerty as Chief Human Resources OfficerAnika Announces the Forthcoming Appointment of Thomas M. Finnerty as Chief Human Resources Officer
finance.yahoo.com - October 23 at 4:58 PM
Chiasma (CHMA) & Anika Therapeutics (ANIK) Head-To-Head AnalysisChiasma (CHMA) & Anika Therapeutics (ANIK) Head-To-Head Analysis
www.americanbankingnews.com - October 23 at 2:08 AM
Insider Selling: Anika Therapeutics Inc. (ANIK) CEO Sells 3,293 Shares of StockInsider Selling: Anika Therapeutics Inc. (ANIK) CEO Sells 3,293 Shares of Stock
www.americanbankingnews.com - October 18 at 8:10 PM
ETFs with exposure to Anika Therapeutics, Inc. : October 18, 2017ETFs with exposure to Anika Therapeutics, Inc. : October 18, 2017
finance.yahoo.com - October 18 at 5:09 PM
Anika Therapeutics Inc. (ANIK) to Release Quarterly Earnings on WednesdayAnika Therapeutics Inc. (ANIK) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 18 at 2:16 AM
ANIK Expands Horizons, FENC Hits Study Goals, IMDZ Abuzz, One More For OpdivoANIK Expands Horizons, FENC Hits Study Goals, IMDZ Abuzz, One More For Opdivo
www.rttnews.com - October 17 at 4:46 PM
Anika Therapeutics (ANIK) Reports Regulatory Approval for MONOVISC in AustraliaAnika Therapeutics (ANIK) Reports Regulatory Approval for MONOVISC in Australia
www.streetinsider.com - October 17 at 4:46 PM
Insider Selling: Anika Therapeutics Inc. (ANIK) CEO Sells 7,124 Shares of StockInsider Selling: Anika Therapeutics Inc. (ANIK) CEO Sells 7,124 Shares of Stock
www.americanbankingnews.com - October 16 at 7:40 PM
Anika Announces Regulatory Approval for MONOVISC® in Australia for the Treatment of Pain Associated with Osteoarthritis of all Synovial JointsAnika Announces Regulatory Approval for MONOVISC® in Australia for the Treatment of Pain Associated with Osteoarthritis of all Synovial Joints
finance.yahoo.com - October 16 at 4:44 PM
Anika to Issue Third-Quarter 2017 Financial Results and Business Highlights on Wednesday, October 25Anika to Issue Third-Quarter 2017 Financial Results and Business Highlights on Wednesday, October 25
finance.yahoo.com - October 11 at 5:26 PM
 Anika Therapeutics Inc. (ANIK) Given $53.00 Consensus Price Target by Brokerages Anika Therapeutics Inc. (ANIK) Given $53.00 Consensus Price Target by Brokerages
www.americanbankingnews.com - October 9 at 2:26 AM
Analyzing Anika Therapeutics (ANIK) & Its PeersAnalyzing Anika Therapeutics (ANIK) & Its Peers
www.americanbankingnews.com - October 3 at 6:20 PM
Viscosupplementation Market By Product, By Region And Segment Forecasts, 2014 - 2025Viscosupplementation Market By Product, By Region And Segment Forecasts, 2014 - 2025
www.prnewswire.com - September 22 at 1:37 PM
Head-To-Head Survey: Anika Therapeutics (ANIK) versus Its PeersHead-To-Head Survey: Anika Therapeutics (ANIK) versus Its Peers
www.americanbankingnews.com - September 16 at 6:30 PM
Viscosupplementation Market Worth $6.52 Billion by 2025: Grand View Research, Inc.Viscosupplementation Market Worth $6.52 Billion by 2025: Grand View Research, Inc.
www.finanznachrichten.de - September 4 at 4:25 PM
Anika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical AffairsAnika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs
finance.yahoo.com - August 28 at 9:02 PM
Analyzing Anika Therapeutics (ANIK) and Syros Pharmaceuticals (SYRS)Analyzing Anika Therapeutics (ANIK) and Syros Pharmaceuticals (SYRS)
www.americanbankingnews.com - August 26 at 12:22 AM
Anika (ANIK) Grows in Orthopedic Medicines on Positive DataAnika (ANIK) Grows in Orthopedic Medicines on Positive Data
finance.yahoo.com - August 15 at 4:52 PM

SEC Filings

Anika Therapeutics (NASDAQ:ANIK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Anika Therapeutics (NASDAQ:ANIK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Anika Therapeutics (NASDAQ ANIK) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.